About Trivascular Technologies (NASDAQ:TRIV)
Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company's solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Industry, Sector and Symbol
Industry Medical Devices & Implants
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-766.90%
Return on Assets-66.97%
Frequently Asked Questions for Trivascular Technologies (NASDAQ:TRIV)
What is Trivascular Technologies' stock symbol?
Trivascular Technologies trades on the NASDAQ under the ticker symbol "TRIV."
How were Trivascular Technologies' earnings last quarter?
Trivascular Technologies Inc (NASDAQ:TRIV) announced its quarterly earnings results on Monday, November, 9th. The medical device company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.05. The medical device company earned $9.50 million during the quarter, compared to analysts' expectations of $9.28 million. Trivascular Technologies had a negative net margin of 143.61% and a negative return on equity of 766.90%. The firm's revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.69) EPS. View Trivascular Technologies' Earnings History.
Who are some of Trivascular Technologies' key competitors?
Some companies that are related to Trivascular Technologies include TSO3 (TOS), Selecta Biosciences (SELB), Mereo BioPharma Group plc (MPH), Allergy Therapeutics plc (AGY), AAC Holdings (AAC), Cascadian Therapeutics (CASC), EndoChoice Holdings (GI), Teligent (TLGT), Agile Therapeutics (AGRX), Recro Pharma (REPH), Merus Labs International (MSLI), Dimension Therapeutics (DMTX), Sinclair Pharma plc (SPH), Alliance HealthCare Services (AIQ), Silence Therapeutics plc (SLN), Knight Therapeutics (GUD), Genesis Healthcare (GEN) and MediWound (MDWD).
How do I buy Trivascular Technologies stock?
Shares of Trivascular Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trivascular Technologies' stock price today?
One share of Trivascular Technologies stock can currently be purchased for approximately $5.87.
How big of a company is Trivascular Technologies?
Trivascular Technologies has a market capitalization of $120.75 million.
How can I contact Trivascular Technologies?
Trivascular Technologies' mailing address is 3910 Brickway Blvd, SANTA ROSA, CA 95403-1070, United States. The medical device company can be reached via phone at +1-707-5438800.
MarketBeat Community Rating for Trivascular Technologies (TRIV)MarketBeat's community ratings are surveys of what our community members think about Trivascular Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Trivascular Technologies (NASDAQ:TRIV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Trivascular Technologies (NASDAQ:TRIV)
Analysts' Ratings History for Trivascular Technologies (NASDAQ:TRIV)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Trivascular Technologies (NASDAQ:TRIV)
Earnings History by Quarter for Trivascular Technologies (NASDAQ TRIV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2015||Q3||($0.71)||($0.66)||$9.28 million||$9.50 million||View||N/A|
|8/4/2015||Q215||($0.73)||($0.73)||$8.78 million||$9.70 million||View||N/A|
|5/5/2015||Q115||($0.68)||($0.77)||$8.48 million||$9.00 million||View||Listen|
|3/3/2015||Q414||($0.65)||($0.72)||$9.54 million||$9.10 million||View||Listen|
|11/10/2014||Q314||($0.63)||($0.69)||$7.90 million||$7.88 million||View||N/A|
|8/6/2014||Q214||($0.66)||($0.87)||$7.54 million||$7.80 million||View||N/A|
|5/14/2014||Q1 14||($1.10)||($1.17)||$6.90 million||$7.00 million||View||N/A|
Earnings Estimates for Trivascular Technologies (NASDAQ:TRIV)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Trivascular Technologies (NASDAQ:TRIV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Trivascular Technologies (NASDAQ TRIV)
Insider Trades by Quarter for Trivascular Technologies (NASDAQ TRIV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/22/2014||Douglas A Roeder||Director||Buy||833,333||$12.00||$9,999,996.00|| |
|4/22/2014||Enterprise Associates 12 New||Major Shareholder||Buy||583,333||$12.00||$6,999,996.00|| |
|4/22/2014||James E Flynn||Insider||Buy||1,065,000||$12.01||$12,790,650.00|| |
Latest Headlines for Trivascular Technologies (NASDAQ TRIV)
Financials are not available for this stock.
Trivascular Technologies (NASDAQ TRIV) Chart for Friday, November, 24, 2017